Eli Lilly

Lilly's oral SERD Ember counts on Verzenio to broaden its glow

Lilly's imlunestrant monotherapy only mounted a PFS benefit in ESR1-mutated tumors, while its pairing with Verzenio moved the needle in a wider group.

Angus Liu Dec 11, 2024 8:15am

heart cardio cardiovascular heart health

Lilly's lipoprotein-blocking heart drug posts midstage trial win

Nov 19, 2024 9:55am

decision path change of plans arrows business decision

Lilly changes lead psoriasis program from $2.4B Dice buyout

Oct 30, 2024 10:00am

Manila folder with CONFIDENTIAL printed on it in red

Alzheimer's trials withheld brain injury risk disclosures: NYT

Oct 24, 2024 11:33am

Beijing International Trade CBD Building Complex China

Eli Lilly unveils 2 new research centers in China

Oct 15, 2024 5:30pm

Lilly picks UK for 1st Gateway Lab in Europe

Oct 14, 2024 10:35am